Get the Stockscreener App
0.4271
7.21%
-0.0332
Pre-market:
.42
-0.0071
-1.66%
Fibrogen Inc stock is traded at $0.4271, with a volume of 855.13K.
It is down -7.21% in the last 24 hours and down -17.99% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
See More
Previous Close:
$0.4603
Open:
$0.4535
24h Volume:
855.13K
Relative Volume:
0.26
Market Cap:
$43.04M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-0.1458
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
+9.43%
1M Performance:
-17.99%
6M Performance:
-9.13%
1Y Performance:
-78.64%
1-Day Range:
$0.413
$0.4871
1-Week Range:
$0.3594
$0.4918
52-Week Range:
$0.18
$2.80
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.4271 | 43.04M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World
Weekly CEO Buys Highlight: Camping World, FibroGen - GuruFocus.com
AstraZeneca’s $160 Million Acquisition of FibroGen China - Global Legal Chronicle
Ropes & Gray Advises FibroGen in $160 Million Sale of Fibrogen China to AstraZeneca - Ropes & Gray LLP
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FibroGen, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 17 - Nasdaq
When Will FibroGen Reveal Its 2024 Performance? Key Date for Investors Announced - StockTitan
FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen announces $30M "at the market" equity offering - Investing.com India
FibroGen announces $30M "at the market" equity offering By Investing.com - Investing.com South Africa
FibroGen Says Entered ATM Equity Offering Sales Agreement Relating To Sale From Time To Time Of Shares Of Common Stock - Marketscreener.com
Form 424B5 FIBROGEN INC - StreetInsider.com
Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary - Scrip
FibroGen Inc Announces Sale of China Subsidiary to AstraZeneca f - GuruFocus.com
Investor Network: FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen sells China biz to AstraZeneca for $160 M - BSA bureau
FibroGen (FGEN) Expected to Announce Quarterly Earnings on Monday - Defense World
FibroGen sells China unit to AstraZeneca for $160 million - MSN
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal - MSN
Moody's Lifts AstraZeneca's Ratings, Revises Outlook to Stable -February 21, 2025 at 11:51 am EST - Marketscreener.com
FibroGen stock holds $10 target amid China unit sale By Investing.com - Investing.com Nigeria
FibroGen stock holds $10 target amid China unit sale - Investing.com
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise - Simply Wall St
AstraZeneca Buys FibroGen China for $160 Million to Gain Access to Anemia Drug -February 21, 2025 at 03:44 am EST - Marketscreener.com
This Small Cap Soared Following Subsidiary Sale Announcement Worth $160M - The Globe and Mail
FibroGen to sell China business, extend cash runway to focus on cancer drugs - The Business Journals
FibroGen sells China unit to AstraZeneca for $160m - Yahoo Finance
FibroGen (FGEN) to Release Earnings on Monday - MarketBeat
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga
FibroGen sells China business to AstraZeneca - The Pharma Letter
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal - MSN
AstraZeneca deepens China presence with FibroGen deal - BioPharma Dive
FibroGen’s Strategic Sale and Pipeline Focus Justify Buy Rating Amid Financial Strength - TipRanks
FibroGen Sells Subsidiary to AstraZeneca for $160M - TipRanks
AstraZeneca to buy FibroGen's China unit for $160 million - MSN
FibroGen stock soars on China unit sale By Investing.com - Investing.com South Africa
FibroGen stock soars on China unit sale - Investing.com India
FibroGen soars on $160 mln China unit sale to AstraZeneca - TradingView
FibroGen Sells China Unit to AstraZeneca in $160 Million DealNews and Statistics - IndexBox, Inc.
FibroGen sells China unit to AstraZeneca in deal worth $160 million By Reuters - Investing.com
FibroGen sells China unit to AstraZeneca in deal worth $160 million -February 20, 2025 at 06:40 am EST - Marketscreener.com
FibroGen sells China unit to AstraZeneca for $160 million (FGEN:NASDAQ) - Seeking Alpha
FibroGen Announces Sale of China Subsidiary to AstraZeneca for Approximately $160 Million - Nasdaq
FibroGen sells China unit to AstraZeneca in deal worth $160 million - TradingView
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million - GlobeNewswire
Inside FibroGen's $160M China Exit: Strategic Pivot or Cash Grab? - StockTitan
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):